On March 27, 2023, MGI and Fujian Berry Oncology Co., Ltd. signed the strategic cooperation agreement. MGI to provide DNBSEQ sequencing platform and automation platform to help Berry Oncology to cooperate in early cancer screening and registration of drug concomitant testing products, so as to accelerate the development of high-quality tumor precision diagnosis and treatment. The signing ceremony was attended by Mou Feng, CEO of MGI, Jiang Hui, COO of MGI, David Zhou, CEO of Berry Oncology, Zhu Hongbin, Vice President, and Wu Jiayan, Director of the Research Institute.

David Zhou, Chief Executive Officer of Berry Oncology, said:

"We are very much looking forward to working with MGI to advance the implementation of the strategic partnership. I believe this will trigger deeper, broader and more sustainable technology and product innovation in the field of early cancer screening, promote the integrated development of the local biotechnology industry chain, accelerate the transformation of national high-tech achievements to the ground, and jointly promote the development of the tumor precision diagnosis and treatment industry, so that the products can serve the people and Let the technology benefit the world."

Mou Feng, Chief Executive Officer of MGI, said:

"As a provider of core tools for life sciences, MGI has been committed to providing an open and collaborative ecosystem for midstream and downstream clinical and research users with a high-quality, advanced equipment platform. Over the past six years, we have built a full line of sequencing products covering high, medium and low throughput, and reduced the cost of sequencing to below US$100, providing an additional choice for users worldwide. We look forward to working with Berry Oncology to leverage our respective strengths for win-win development and to work together to bring deeper and more comprehensive breakthroughs in the field of oncology precision medicine. In the future, MGI will continue to adhere to the underlying innovation, persist in empowering the field of precision medicine and contribute to the universal access to gene sequencing technology."

Currently, high-throughput sequencing technology has a high level of detection maturity in early cancer screening and early screening of multiple tumour types. As one of the few companies in the world that can mass-produce clinical-grade gene sequencers, MGI has a sequencing product layout that can cover different application scenarios, and its data output quality and cost have industry-leading advantages. HURIDAY is a representative company in the global oncology genetic testing industry and early cancer screening track. By joining forces, the two companies will further build a core product pipeline for the whole cycle of oncology precision diagnosis and treatment, further optimize and balance the performance, cost and accessibility of cancer early screening products, and promote the application and benefit of gene technology.

As of December 31, 2021, MGI has served more than 1,300 users worldwide and has been empowering in several research and clinical areas. MGI adheres to the concept of "innovation and intelligence leading life science and technology", always insists on innovation, continues to build an open and win-win industry ecology through advanced platform and technology, and contributes to the platform power for precision cancer diagnosis and treatment.